Use of anti-mu monoclonal antibody as a therapeutic approach to achieve depletion of xenoreactive natural antibodies.
Soares
M
M
Experimental Immunology Unit, Faculty of Medicine, University of Louvain, Brussels, Belgium.
Nisol
F
F
Bach
F H
FH
Bazin
H
H
Latinne
D
D
D000818:Animals; D000910:Antibodies, Heterophile / Q000097:blood / Q000302:isolation & purification*; D000911:Antibodies, Monoclonal; D001402:B-Lymphocytes / Q000276:immunology*; D004730:Endothelium, Vascular / Q000276:immunology; D005260:Female; D006168:Guinea Pigs; D007075:Immunoglobulin M / Q000097:blood / Q000302:isolation & purification*; D007166:Immunosuppressive Agents / Q000494:pharmacology; D008297:Male; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D010951:Plasma Exchange; D051381:Rats; D011919:Rats, Inbred Strains; D013154:Spleen / Q000276:immunology; D013156:Splenectomy
D000910:Antibodies, Heterophile; D000911:Antibodies, Monoclonal; D007075:Immunoglobulin M; D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid